|
Open label trial exploring a switch from oral medications, to risperidone depot microspheres Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or professional assistance by using a genuine doctor. We aren't mDs. Always consult your physician about Open label trial exploring a switch from oral medications, to risperidone depot microspheres conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Open label trial exploring a switch from oral medications, to risperidone depot microspheres Clinical research trials and Open label trial exploring a switch from oral medications, to risperidone depot microspheres health trials occur in a lot of of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the potency of new does drugs. The role of the studies / undertakings is to figure out specific human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all sorts of conditions, including Open label trial exploring a switch from oral medications, to risperidone depot microspheres. Open label trial exploring a switch from oral medications, to risperidone depot microspheres Clinical Trials and other clinical trials permit volunteers to get medical treatment choices before they are available to the general public. Many times the test subjects get professional assistance for free of charge, and occasionally they are compensated for their time. Sometimes there is a cost for a Open label trial exploring a switch from oral medications, to risperidone depot microspheres clinical trial. Human subjects often get the best healthcare possible for their Open label trial exploring a switch from oral medications, to risperidone depot microspheres condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, medical hazards (perhaps life-threatening), and/or the treatment being ineffectual. Trials are federally governed with exacting guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "O" Clinical Trials Conditions > Open label trial exploring a switch from oral medications, to risperidone depot microspheres Open label trial exploring a switch from oral medications, to risperidone depot microspheres
Open label trial exploring a switch from oral medications, to risperidone depot microspheres
For Condition: Schizophrenia
Status: Completed
Sponsor(s): Johnson & Johnson Pharmaceutical Research and Development, L.L.C. ,
Synopsis: The purpose of this trial is to look at the effectiveness of patients being switched from haldol, seroquel or zyprexa to biweekly risperidone injections.
Details:
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: - Diagnosis of schizophrenia according to the DSM IV criteria (295.10, 295.20, 295.30, 295.60, 295.90); - Currently treated with either oral haloperidol, quetiapine fumarate, or olanzapine for 4 months prior to trial entry; - PANSS score of <80; on each of the following PANSS items: conceptual disorganization, hallucinatory behavior, suspiciousness, unusual thought content, the score is < 4; - Subject with a body mass index < 35 at screening
Total Enrollment: 141
Location and Contact Information:
Sharp Mesa-Vista Hospital
San Diego, California, 92123
United States
St. Paul Medical Center
Dallas, Texas, 75235
United States
Comprehensive Clinical Research,
Clementon, New Jersey, 08021
United States
LSU Behavioral Research Institute
New Orleans, Louisiana, 70112
United States
Berma Research Group
Hialeah, Florida, 33016
United States
Hawaii Clinical Research Center
Honolulu, Hawaii, 96826
United States
Manhattan Psychiatric Center
New York City, New York, 10035
United States
ICSL - Clinical Studies
Melbourne, Florida, 32935
United States
Cedars-Sinai Medical Center
Los Angeles, California, 90048
United States
Comprehensive NeuroScience, Inc
Washington D.C., District of Columbia, 20016
United States
Univ. of Texas Health Science Center at San Antonio
San Antonio, Texas, 78229-3900
United States
Behavioral Medical Research
Staten Island, New York, 10305
United States
IPS Research
Oklahoma City, Oklahoma, 73103
United States
Alexian Brothers Behavior Health Hospital
Hoffman Estates, Illinois, 60194
United States
Community Clinical Research, Inc
Austin, Texas, 78756
United States
ClinSearch Inc.
Kenilworth, New Jersey, 07033
United States
Comprehensive NeuroScience-IPR
Cerritos, California, 90703
United States
Clinical Studies Center
Little Rock, Arkansas, 72205
United States
Affiliated Research Institute
San Diego, California, 92108
United States
Medical College of Virginia
Richmond, Virginia, 23298
United States
Clinical Research Services @Tennessee Christian Medical Center
Madison, Tennessee, 37115
United States
Neuropsych Research Associates
New York City, New York, 10128
United States
South Carolina VA Medical Center
Charleston, South Carolina, 29401-5799
United States
Carman Research
Smyrna, Georgia, 30080
United States
VA Medical Center
Coatesville, Pennsylvania, 19320-2096
United States
Centers for Behavioral Health
Rockville, Maryland, 20850
United States
BMR HealthQuest
Glendale, California, 91206
United States
Med Labs Research of Houston, Inc.
Houston, Texas, 77057
United States
Neurobehavior Research Inc.
Lawrence, New York, 11559
United States
Additional Information:
Study ID Numbers: RIS-USA-259;
Study Start Date: July 2001
Record last reviewed: January 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00034775
Other Schizophrenia Studies:
1. Extended Release OROS Paliperidone in treatment of Schizophrenia (double blind, placebo-controlled trial, with Olanzapine arm)
2. Self-Management Therapy for Youth with Schizophrenia
3. Magnetic Resonance Imaging (MRI) of Neuropsychiatric Patients and Healthy Volunteers
4. Treating Drug-Resistant Childhood Schizophrenia
5. Genetic Study of Schizophrenia
Related Studies:
Other Schizophrenia Clinical Trials
Other Arkansas Clinical Trials
Other Little Rock Clinical Trials
Open label trial exploring a switch from oral medications, to risperidone depot microspheres
|
|
|
|
|
|
|
|